title: Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
abstract: BACKGROUND
  Sequential therapy (SQT) is effective in the eradication of Helicobacter pylori and could become an alternative to standard triple therapy (STT).
  
  
  OBJECTIVE
  To compare the efficacy and tolerability of SQT, for either 8 or 10 days, with a 7-day STT.
  
  
  METHODS
  A total of 270 naive H. pylori-positive patients were randomized to receive: SQT for 8 days (SQT-8, n=90) or 10 days (SQT-10, n=90) including esomeprazole 20 mg twice daily (bid) associated with amoxicillin 1000 mg bid (early 4 and 5 d, respectively), followed by esomeprazole 20 mg bid associated with clarithromycin 500 mg bid plus tinidazole 500 mg bid (last 4 and 5 d, respectively); STT (n=90) including esomeprazole 20 mg bid plus amoxicillin 1000 mg bid and clarithromycin 500 mg bid for 7 days. Tolerability was assessed by scoring the severity of symptoms.
  
  
  RESULTS
  Eradication rates after SQT-8 and SQT-10 were higher than that of after STT at both intention-to-treat (83% and 86% vs. 66%, P<0.02) and per-protocol analysis (90% and 88% vs. 75%, P<0.05), whereas no difference was found between the 2 SQTs.
  
  
  CONCLUSIONS
  This study shows that SQT, for 8 or 10 days, is well tolerated and highly effective in H. pylori eradication and could represent a valid alternative to STT. Further studies, with more power, on larger populations and from other countries are necessary to validate the present findings.
authors.affiliation: Gastroenterology Unit, Department of Internal Medicine, University of Rome "Tor Vergata," Rome, Italy. omeroalessandro.paoluzi@ptvonline.it
authors.forename: Omero Alessandro
authors.initials: OA
authors.lastname: Paoluzi
authors.forename: Emanuela
authors.initials: E
authors.lastname: Visconti
authors.forename: Fabio
authors.initials: F
authors.lastname: Andrei
authors.forename: Claudio
authors.initials: C
authors.lastname: Tosti
authors.forename: Raffaella
authors.initials: R
authors.lastname: Lionetti
authors.forename: Enrico
authors.initials: E
authors.lastname: Grasso
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ranaldi
authors.forename: Italo
authors.initials: I
authors.lastname: Stroppa
authors.forename: Francesco
authors.initials: F
authors.lastname: Pallone
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001944:Breath Tests; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D064098:Esomeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014011:Tinidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D014011:Tinidazole; D000658:Amoxicillin; D017291:Clarithromycin; D064098:Esomeprazole